- To date, the only accredited screening tests are the “combined”, being based on nuchal translucency and placental proteins. Regarding these tests, our scientific research centre, following current institutional guidelines, proposes the ones that have been experimented in the national population (SCA-TEST);
- The only diagnostic tests for foetal genetic and genomic anomalies are the chorionic villus sampling (CVS) and the amniocentesis which currently provoke the same levels of abortion risk as in the general population (6–9). These methods, in fact, since the introduction of modern and tested genomic techniques using CGH, have been increasingly used in diagnostics;
- The routine and diagnostic utilization of a test based on the research of foetal DNA in maternal blood, today, can no longer be proposed as a first-choice test. Even though the pregnant mother requests the test herself, it is necessary to provide detailed and explicit information regarding its limits (10–12).
Regarding the legal and financial aspects connected to the use of these new screening tests, some people have criticized the high costs and excessive cost/benefit ratio, commercial interests and, finally, the legal complications that have already arisen from the introduction in the commerce of these techniques.
These aspects represent further elements to be taken into consideration so they can be better developed and possibly lead to future clinical use (13–15).
Benn, Peter., (Chair); Borell, A.; Chiu, R.; Cuckle, H.; Dugoff, L.; Faas, B.; Gross, S.; Johnson, J.; Maymon, R.; Norton, M.; Odibo, A.; Schielen, P.; Spencer, K.; Huang, T.; Wright, D.; Yaron, Y. Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. 2013 April;
ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Gregg AR, Gross SJ, Best RG, Monaghan KG, Bajaj K, Skotko BG, Thompson BH, Watson MS. The Noninvasive Prenatal Screening Work Group of the American College of Medical Genetics and Genomics.
American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy.
Obstet Gynecol. 2012 Dec;120(6):1532–4.
CTAF© 2012 California Technology Assessment Forum.
Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D’Alton ME. Pregnancy loss rates after mid trimester amniocentesis.
Obstet Gynecol. 2006 Nov;108(5):1067–1072.
Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center’s 16-year experience.
Obstet Gynecol. 2008 Mar;111(3):589–95.
Giorlandino C, Cignini P, Cini M, Brizzi C, Carcioppolo O, Milite V, Coco C, Gentili P, Mangiafico L, Mesoraca A, Bizzoco D, Gabrielli I, Mobili L. Antibiotic prophylaxis before second-trimester genetic amniocentesis (APGA): a single-centre open randomised controlled trial.
Prenat Diagn. 2009 Jun;29(6):606–12.
CHAPTER 7 - Prenatal Genetic Diagnosis. 5th ed. 2007. Gabbe Obstetrics: Normal and Problem Pregnancies.
van den Heuvel A, Chitty LS, Hogg J, Marteau TM. Will noninvasive prenatal diagnosis using free fetal nucleic acids in maternal blood erode informed choices?
Prenat Diagn. 2008;28:S16.
Marteau TM, Chitty LS. Fetal sexing: Global Perspectives on Practices.
Ethics and Policy Prenat Diagn. 2006;26:597–647.
Wright, C. Cell-free Fetal Nucleic Acids for Non-invasive Prenatal Diagnosis, report of the UK Expert Working Group. Cambridge: PHG Foundation; 2009.
Brady P, Ardui S, Vermeesch JR. The Future of Prenatal Cytogenetics: From Copy Number Variations to Non-invasive Prenatal Testing.
Curr Genet Med Reports. 2013 Jun;1(2):91–98.
Nicholas J, Wald NJ, Jonathan P. Best wick Incorporating DNA sequencing into current prenatal screening practice for Down’s syndrome.
PLOS ONE. 2013;8(3):e58732.
Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S. Commercial landscape of non-invasive prenatal testing in the United States.
Prenat Diagn. 2013 Jun;33(6):521–31.